PLUS THERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Indicates management contract or compensatory plan or arrangement.

Portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv).

† Furnished herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

PLUS THERAPEUTICS, INC.
By:	/s/ Marc H. Hedrick, MD
	Marc. H. Hedrick, MD
	President & Chief Executive Officer
	March 5, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Richard J. Hawkins
SIGNATURE	TITLE	DATE
/s/ Richard J. Hawkins	Chairman of the Board	March 5, 2024
/s/ Marc H. Hedrick, MD	President & Chief Executive Officer (Principal Executive Officer)	March 5, 2024
Marc H. Hedrick, MD
/s/ Andrew Sims	Chief Financial Officer and VP of Finance (Principal Financial and Accounting Officer)	March 5, 2024
Andrew Sims
/s/ An van Es-Johansson, MD	Director	March 5, 2024
An van Es-Johansson, MD
/s/ Greg Petersen	Director	March 5, 2024
Greg Petersen
/s/ Howard Clowes	Director	March 5, 2024
Howard Clowes
/s/ Robert Lenk	Director	March 5, 2024
Robert Lenk

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.